LEGAL STATUS — verified 10 Aug 2026: DEA notices of intent to temporarily Schedule I concentrated 7-OH (above threshold) and related analogues are published; no temporary scheduling order located yet — recheck the Federal Register before counseling.

Treatment framework

Build the bridge before the cliff.

Clinician-facing pathways from emerging evidence and OUD practice. Not individualized dosing instructions and not a patient self-induction recipe.

Treatment bridge metaphor linking dependence to care pathways
Regulation without access to care leaves predictable casualties in the gap.
A 2026 series described nine patients on purified 7-OH products with successful buprenorphine initiation (standard or low-dose) and no precipitated withdrawal in that series. A separate OTP series supports methadone feasibility for selected kratom/7-OH use disorder. These are early signals—not universal protocols.

Governing principle

Treat the patient’s exposure, physiology, and clinical state. Commercial products may contain concentrated 7-OH, mitragynine pseudoindoxyl, MGM analogues, other alkaloids, or mislabeled quantities. Direct human PK for repeated high-dose purified 7-OH remains inadequately defined.

Pathway A — Standard buprenorphine initiation

Reasonable when product history is reasonably clear and the patient shows convincing, progressive opioid withdrawal. Use the clinician’s established protocol with reassessment after each step.

There is no evidence-based universal minimum interval after the last 7-OH dose. Rules such as “always safe after 12, 16, or 24 hours” are not supportable.

Pathway B — Low-dose buprenorphine initiation

Consider when last exposure is uncertain; q1–3h redosing with inability to tolerate abstinence; possible mixed exposure (mitragynine, MP, MGM, fentanyl); prior precipitated withdrawal; or high consequence of a withdrawal spike. Local protocols and monitoring capacity determine the schedule. Educational notes on microinduction / tapered crossover rationale are in downloads—not a public milligram ladder.

Pathway C — Methadone

Appropriate when buprenorphine is unsuitable or unsuccessful, preference or OTP structure fits, or high tolerance warrants it. Apply standard OUD safeguards (QTc, sedating co-medications, respiratory disease).

Pathway D — Symptomatic treatment without MOUD

May fit mild, brief exposure without compulsive use or high substitution risk. Usually a poor stand-alone strategy for frequent redosing, nocturnal withdrawal, or high likelihood of seeking another opioid.

Adjuncts and pitfalls

Familiar withdrawal adjuncts (alpha-2 agonists, antiemetics, antidiarrheals when appropriate, nonopioid analgesics, hydration, careful sleep support) can help. Avoid reflexively stacking sedatives. Do not start naltrexone while still physically dependent without an adequate opioid-free interval.

Prevent the predictable failure mode

Counsel that counterfeit pills and street opioids may contain fentanyl, and that trying to reproduce a familiar 7-OH effect is not dose-equivalent or safe. Supply naloxone. Plan follow-up and maintenance versus taper explicitly.

Clinician downloads

Printable assessment · Clinician hub · Withdrawal course · Patient guide · All downloads